Hims & Hers Slides 10% Hours Before Q3 Print; Street Eyes 6-Cent Profit
HIMS sits 70% above its 52-week low of $13.74 on elevated volume (2.4× avg).
Summary
Hims & Hers is down 10.31% at $23.32 Monday, hours before its third-quarter report lands after the close. The setup is a low bar: Wall Street wants 6 cents of EPS and $892.89 million in revenue, roughly 19% above the $753.21 million posted in Q2. Last quarter was a split decision — revenue beat at $753.21 million while EPS came in at a 37-cent loss against a 3-cent loss expected — so the question is whether both lines finally move the same way. Management raised full-year 2026 sales guidance to $3.1 billion-$3.3 billion last quarter, and any lift above that range would extend the raise. The tape is also carrying regulatory noise: HHS enforcement discretion on compounded peptides from late October and the FDA's September warning on unapproved compounded GLP-1s remain live issues for the weight-loss business. The after-close print is the immediate binary.
At the time of this announcement, HIMS was trading at $23.30 on NYSE in the Life Sciences sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $13.74 to $42.70. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Benzinga.